102491-73-6

Usage

Uses

Colchicine intermediate.

Upstream product

• 102491-71-4 (+/-)-N-(trifluoroacetyl)deacetylcolchicine 
• 186581-53-3 diazomethane 
• 73307-44-5 7-amino-10-hydroxy-1,2,3-trimethoxy-6,7-dihydro-5H-benzo[a]heptalen-9-one 
• 143731-66-2 (7RS)-7-hydroxy-1,2,3,10-tetramethoxy-6,7-dihydrobenzo[a]heptalen-9(5H)-one 
• 102491-70-3 (+/-)-N-(trifluoroacetyl)deacetylcolchiceine 
• 64-86-8 colchicine 
• 1268129-23-2 acetyl-(1,2,3,10-tetramethoxy-9-oxo-5,6,7,9-tetrahydro-benzo[a]heptalen-7-yl)-carbamic acid t-butyl ester 
• 1268129-30-1 (1,2,3,10-tetramethoxy-9-oxo-5,6,7,9-tetrahydro-benzo[a]heptalen-7-yl)-carbamic acid t-butyl ester 
• 143702-47-0 C₂₁H₂₆O₇ 
• 209810-38-8 N-(5,6,7,9-tetrahydro-1,2,3,10-tetramethoxy-9-oxobenzo[a]heptalen-7-yl) acetamide 
• 143702-48-1 (7RS)-methanesulfonic acid 1,2,3,10-tetramethoxy-9-oxo-5,6,7-trihydrobenzo[a]heptalen-7-yl ester 
• 143702-49-2 (7RS)-7-azido-1,2,3,10-tetramethoxy-6,7-dihydrobenzo[a]heptalen-9(5H)-one 

Downstream Products

• 209810-38-8 N-(5,6,7,9-tetrahydro-1,2,3,10-tetramethoxy-9-oxobenzo[a]heptalen-7-yl) acetamide 
• 102419-91-0 (+)-N-deacetylcolchicine 
• 64-86-8 colchicine 
• 26195-65-3 N-(5,6,7,9-tetrahydro-1,2,3,10-tetramethoxy-9-oxobenzoheptalen-7-yl)-(S)-2,2,2-trifluoroacetamide 
• 75520-89-7 (+)-colchicine 

Relevant academic research and scientific papers

Cell-mediated assembly of phototherapeutics

Light-activatable drugs offer the promise of controlled release with exquisite temporal and spatial resolution. However, light-sensitive prodrugs are typically converted to their active forms using short-wavelength irradiation, which displays poor tissue penetrance. We report herein erythrocyte-mediated assembly of long-wavelength-sensitive phototherapeutics. The activating wavelength of the constructs is readily preassigned by using fluorophores with the desired excitation wavelength λex. Drug release from the erythrocyte carrier was confirmed by standard analytical tools and by the expected biological consequences of the liberated drugs in cell culture: methotrexate, binding to intracellular dihydrofolate reductase; colchicine, inhibition of microtubule polymerization; dexamethasone, induced nuclear migration of the glucocorticoid receptor.

PHOTO-RESPONSIVE COMPOUNDS

The presently-disclosed subject matter provides photo-responsive compounds and methods of use thereof. The photo-responsive compounds comprise a photolabile molecule and a fluorophore appended to the photolabile molecule. The presently- disclosed subject matter further relates to a drug delivery system that uses red blood cells to deliver photo-responsive compounds for the treatment of disease.

COLCHICINE DERIVATIVES OR PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF, METHOD FOR PREPARING SAID DERIVATIVES, AND PHARMACEUTICAL COMPOSITION COMPRISING SAID DERIVATIVES

The present invention relates to colchicine derivatives expressed in chemical formula 1, or to pharmaceutically acceptable salts thereof, to a method for preparing said derivatives, and to a pharmaceutical composition comprising said derivatives. The colchicine derivatives according to the present invention exhibit superior immunomodulatory effects as compared with conventional immunomodulators or colchicines, and therefore can be valuably used as an immunomodulator for modulating an acute or chronic immune response in organ transplantation.

COLCHICINE DERIVATIVES OR PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF, METHOD FOR PREPARING SAID DERIVATIVES, AND PHARMACEUTICAL COMPOSITION COMPRISING SAID DERIVATIVES

The present invention relates to colchicine derivatives expressed in chemical formula 1, or to pharmaceutically acceptable salts thereof, to a method for preparing said derivatives, and to a pharmaceutical composition comprising said derivatives. The colchicine derivatives according to the present invention exhibit superior immunomodulatory effects as compared with conventional immunomodulators or colchicines, and therefore can be valuably used as an immunomodulator for modulating an acute or chronic immune response in organ transplantation.

Total synthesis of (-)-colchicine via a Rh-triggered cycloaddition cascade

(Chemical Equation Presented) A synthesis of the antimitotic alkaloids (-)-colchicine and (-)-isocolchicine is reported. Important steps are (a) enantioselective transfer-hydrogenation of an alkynone, (b) iodine/magnesium exchange with subsequent aromatic

COLCHICINE DERIVATIVES

Certain N-deacetylcolchicine and N-deacetylthiocolchine derivatives are described wherein the 7-N position on the B ring is substituted with the group —C(O)—(CHR4)m-AR, wherein m is an integer of 0-10, A is S, O, N or a covalent bond

Mammalian DNA topoisomerase II inhibitor and method

A novel antiproliferative drug and methods are disclosed. The drug has the general structural formula: STR1 where R1=OR1 ', SR1 ', or N(R1 'R1 ")2, where R1 ' and R1 " are H or lower alkyl groups, and R2 is an acylamino, or aroylamino group. The compound is useful for inhibiting cell proliferation in drug-resistant tumor cells. Also disclosed is a method of chemical converting a colchicine derivative to form an active inhibitor of DNA topisomerase II.

A Biomimetic and Fully Regiocontrolled Total Synthesis of (+/-)-Colchicine

The first fully regiocontrolled total synthesis of the alkaloid colchicine 1 is described; the key step of the reaction sequence is the efficient biomimetic conversion of the ?-homo-o-benzoquinone monoacetal 11 into the α-tropolone-O-methyl ether 13.